Evommune, Inc. cash flow statement EVMN

In fiscal 2025, which ended Dec 31, 2025, Evommune, Inc. used $76.4 million of cash from operations. It spent $235,000 on capital expenditures. Free cash flow was negative, at -$76.7 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
Operating
Depreciation and amortization
—
1
Stock-based compensation
—
6
Operating cash flow
—
-76
Investing
Capital expenditures
—
0
Investing cash flow
—
-115
Financing
Financing cash flow
—
221
Change in cash
Net change in cash
—
29
Free cash flow
—
-77
Per share
Free cash flow per share
—
-12.49
Ratios
Free cash flow margin
—
-589.82%
Capital expenditures to revenue
—
1.81%
Stock-based compensation to revenue
—
45.05%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
EVMN (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Palo Alto, CA
SEC filer status
, Emerging growth company
SEC CIK
2044725

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.